- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Wellthy Extends Global Footprint, Appoints Veteran Commercial Leader
Wellthy Therapeutics announced the appointment of Theo Ahadome as Chief Business Officer.
“We have all seen how well-established technologies in one region can be applied in other geographies, leapfrog and accelerate the advancement of global innovation. Wellthy is in a firm position to lead the evolution of the global digital care industry - from point solutions to true patient companions that solve challenges in all stages of the disease and treatment journey. I am excited about the health equity mission of Wellthy, its robust operating system, and proven success delivering outcomes in various therapeutic areas,” added Theo Ahadome.
Before joining Wellthy Therapeutics, Theo was Senior Vice President of Commercial at Happify Health (now Twill), where he led the company’s specialty solutions partnerships. He also previously held commercial positions at Science 37 and Amgen. Theo holds a Masters in Business Administration (MBA) from Duke University, Fuqua School of Business and an MPhil in Technology Policy from the University of Cambridge.
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
